Seraphim Pallas, M.D. Internal Medicine - Hematology & Oncology Medicare: Accepting Medicare Assignments Practice Location: 5680 Bow Pointe Dr, Suite 202, Clarkston, MI 48346 Phone: 248-922-6650 |
News Archive
Researchers seeking to learn more about stroke by studying how the body responds to toxins in snake venom are this week releasing new findings that they hope will aid in the development of therapies for heart disease and, surprisingly, cancer. The Japanese team is reporting in a Journal of Biological Chemistry "Paper of the Week" that they are optimistic that inhibiting a protein found on the surface of blood cells known as platelets may combat both irregular blood clotting and the spread of certain cancers throughout the body.
A new Tel Aviv University study finds that gene deletion or deficiency in neurons is responsible for the abnormal hypersocial behavior associated with Williams syndrome, a rare disorder affecting 1 in 10,000 people around the world.
GNA/Peace FM examines the recent creation of a local and international taskforce to help shorten the window of time between the completion of the clinical trial of the RTS,S malaria vaccine - currently being tested across Africa - and licensure and vaccine distribution. According to the news service, scientists recently launched a Phase III trial of the RTS,S vaccine in Kintampo, Ghana, which will include 1,200 children, between the ages of 6-12 weeks and 5-17 months.
Surgeons at University Hospitals Case Medical Center, Cleveland, are working to reduce serious complications that have been known to occur with colorectal operations.
EnGeneIC Ltd., an emerging biopharmaceutical company focused on developing its proprietary EDV™ nanocell platform for the targeted delivery of cancer therapeutics, today announced that the first patient has been dosed in its Phase 1 Tailored-EDV trial. The trial is being conducted at the Northern Cancer Institute in Sydney, Australia.
› Verified 4 days ago